[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l). According to the MIC 90% values, the corresponding grade of activity was as follows: ciprofloxacin, ofloxacin, norfloxacin, pefloxacin, enoxacin, pipemidic acid, enoxacin and nalidixic acid. After an oral dose of 400 mg of ofloxacin, the mean peak serum concentration of ten patients was 5.5 mg/l. The mean renal excretion during 24 hours was 41%. In ten patients undergoing transurethral resection of the prostate, the median serum concentration was 1.87 mg/l and the median prostatic adenoma tissue concentration 1.20 mg/kg 14.5 to 19 hours after oral administration of 400 mg ofloxacin. Due to the in vitro activity and the concentrations obtained in serum, urine and tissue, ofloxacin appears to be well suited for treatment of complicated UTI.
K G
KG
Naber
D
D
Adam
R
R
Wittenberger
B
B
Bartosik-Wich
D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000378:metabolism* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D003428:Cross Infection / Q000188:drug therapy / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000378:metabolism* / Q000627:therapeutic use; D011467:Prostate / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D059005:Topoisomerase II Inhibitors; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism*
D000892:Anti-Infective Agents, Urinary; D010078:Oxazines; D059005:Topoisomerase II Inhibitors; D015242:Ofloxacin
In vitro-Aktivität, Serum-, Urin- und Prostataadenom-Gewebekonzentrationen von Ofloxacin bei urologischen Patienten mit komplizierten Harnwegsinfektionen.